Okami Medical Enrolls First Patient in ALPHA Registry

New registry to evaluate safety and effectiveness of LOBO Vascular Occlusion System for peripheral vascular conditions

Apr. 7, 2026 at 8:30pm

Got story updates? Submit your updates here. ›

A translucent, ghostly X-ray photograph of the LOBO vascular occlusion device, revealing its skeletal, glowing internal structure against a dark background, conceptually illustrating the advanced medical technology behind this embolization system.An X-ray view of the LOBO vascular occlusion device reveals its intricate internal structure, showcasing the innovative technology behind this breakthrough embolization solution.Aliso Viejo Today

Okami Medical, a medical technology company, has announced the enrollment of the first patient in the ALPHA Registry, a prospective, multicenter registry evaluating the safety and effectiveness of the LOBO Vascular Occlusion System for patients suffering from a variety of peripheral vascular conditions, including arterial hemorrhage and pulmonary arteriovenous malformation.

Why it matters

The ALPHA Registry is a key step in Okami's broader clinical strategy to deliver robust evidence on the real-world use of the LOBO device in vascular embolization procedures. This comprehensive registry will serve as a foundation for the continued expansion of clinical evidence on the LOBO vascular occlusion system, which is designed to provide controlled, mechanical occlusion of peripheral vessels across a broad range of anatomies.

The details

The LOBO device's proprietary HD BRAID construction optimizes deliverability, occlusivity, and stability, enabling physicians to quickly achieve reliable occlusion while maintaining procedural efficiency. The ALPHA Registry is uniquely structured to assess distinct outcomes across multiple clinical conditions, with the ability to gather key clinical insights that will help physicians enhance patient care in embolization.

  • The first patient was enrolled in the ALPHA Registry on April 7, 2026.

The players

Okami Medical

A medical technology company pioneering novel vascular embolization solutions.

LOBO Vascular Occlusion System

A one-of-a-kind embolization system designed to provide controlled, mechanical occlusion of peripheral vessels across a broad range of anatomies.

ALPHA Registry

A prospective, multicenter registry evaluating the safety and effectiveness of the LOBO Vascular Occlusion System for patients suffering from a variety of peripheral vascular conditions.

Ningcheng "Peter" Li, MD

A physician at UMass Memorial Medical Center who enrolled the first patient in the ALPHA Registry.

Neil J. Resnick, MD

A physician at UMass Memorial Medical Center who enrolled the first patient in the ALPHA Registry.

Nima Kokabi, MD

A site investigator at UNC Health System for the ALPHA Registry.

Got photos? Submit your photos here. ›

What they’re saying

“This case demonstrates the utility of the LOBO system in pulmonary arteriovenous malformation (PAVM) treatment. Multiple PAVMs were treated with LOBO, with one device implanted per feeding artery, and intraprocedural occlusion achieved in under two minutes per vessel. This significant milestone kickstarts a substantial effort to generate meaningful clinical evidence supporting the LOBO device.”

— Ningcheng "Peter" Li, MD, Physician, UMass Memorial Medical Center

“The LOBO vascular occluder is a one-of-a-kind embolization system that delivers fast and predictable occlusion across a wide variety of vascular conditions. The ALPHA Registry is uniquely structured to assess distinct outcomes across multiple clinical conditions, with the ability to gather key clinical insights that will help physicians enhance patient care in embolization. We are proud to contribute to the growing body of clinical evidence supporting LOBO and continue to advance this therapy forward.”

— Nima Kokabi, MD, Site Investigator, UNC Health System

What’s next

Okami plans to enroll up to 500 patients across up to 30 sites in the ALPHA Registry, which will serve as a foundation for the continued expansion of clinical evidence on the LOBO vascular occlusion system.

The takeaway

The ALPHA Registry represents a significant milestone in Okami's efforts to generate robust clinical evidence supporting the LOBO vascular occlusion system, which is designed to provide fast and predictable occlusion for a variety of peripheral vascular conditions. The registry's unique structure will enable the collection of key insights to help physicians enhance patient care in embolization procedures.